NEW YORK – ERS Genomics said on Monday that the European Patent Office (EPO) has upheld one of the CRISPR patents the company holds.
ERS was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier. This CRISPR IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna, and is separate from genome editing patents held by the Broad Institute.